Literature DB >> 27573760

Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia/lymphoma: a report of two cases.

Yukie Tsubokura1, Atsushi Satake2, Masaaki Hotta1, Hideaki Yoshimura1, Shinya Fujita1, Yoshiko Azuma1, Takahisa Nakanishi1, Aya Nakaya1, Tomoki Ito1, Kazuyoshi Ishii1, Shosaku Nomura1.   

Abstract

A humanized anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, mogamulizumab (MOG), has been shown to be safe and effective in the treatment of relapsed/refractory adult T-cell leukemia/lymphoma (ATLL). MOG depletes ATLL cells as well as regulatory T cells (Tregs), as CCR4 is expressed on these cells as well. In this context, pretransplant treatment with MOG may induce severe graft-versus-host disease (GVHD) in allogeneic hematopoietic stem-cell transplantation (HSCT). However, the influence of MOG on allogeneic HSCT, including its induction of GVHD, is unclear. In this report, we describe two patients treated with MOG who subsequently underwent allogeneic HSCT. They did not develop severe GVHD or treatment-related complications. In addition, we examined the kinetics of Tregs in the second case. Finally, we suggest that the detrimental effects of MOG can be avoided, which should be prospectively evaluated in future studies.

Entities:  

Keywords:  ATLL; Graft-versus-host disease; Mogamulizumab; Regulatory T cell

Mesh：

Substances：

Year:  2016        PMID： 27573760     DOI： 10.1007/s12185-016-2087-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.319


  20 in total

1.  Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality.

Authors:  Y Inoue; S Fuji; R Tanosaki; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2015-12-21       Impact factor: 5.483

2.  Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.

Authors:  Takashi Ishida; Tatsuro Joh; Naokuni Uike; Kazuhito Yamamoto; Atae Utsunomiya; Shinichiro Yoshida; Yoshio Saburi; Toshihiro Miyamoto; Shigeki Takemoto; Hitoshi Suzushima; Kunihiro Tsukasaki; Kisato Nosaka; Hiroshi Fujiwara; Kenji Ishitsuka; Hiroshi Inagaki; Michinori Ogura; Shiro Akinaga; Masao Tomonaga; Kensei Tobinai; Ryuzo Ueda
Journal:  J Clin Oncol       Date:  2012-02-06       Impact factor: 44.544

3.  Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109).

Authors:  Kunihiro Tsukasaki; Kensei Tobinai; Masanori Shimoyama; Mitsuo Kozuru; Naokuni Uike; Yasuaki Yamada; Masao Tomonaga; Koichi Araki; Masaharu Kasai; Kiyoshi Takatsuki; Mitsutoshi Tara; Chikara Mikuni; Tomomitsu Hotta
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

4.  Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients.

Authors:  Koji Kurose; Yoshihiro Ohue; Hisashi Wada; Shinsuke Iida; Takashi Ishida; Takashi Kojima; Toshihiko Doi; Susumu Suzuki; Midori Isobe; Takeru Funakoshi; Kazuhiro Kakimi; Hiroyoshi Nishikawa; Heiichiro Udono; Mikio Oka; Ryuzo Ueda; Eiichi Nakayama
Journal:  Clin Cancer Res       Date:  2015-10-01       Impact factor: 12.531

5.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

Authors:  Claudio G Brunstein; Jeffrey S Miller; Qing Cao; David H McKenna; Keli L Hippen; Julie Curtsinger; Todd Defor; Bruce L Levine; Carl H June; Pablo Rubinstein; Philip B McGlave; Bruce R Blazar; John E Wagner
Journal:  Blood       Date:  2010-10-15       Impact factor: 22.113

6.  Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).

Authors:  Koji Kurose; Yoshihiro Ohue; Eiichi Sato; Akira Yamauchi; Shingo Eikawa; Midori Isobe; Yumi Nishio; Akiko Uenaka; Mikio Oka; Eiichi Nakayama
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609

7.  VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.

Authors:  Kunihiro Tsukasaki; Atae Utsunomiya; Haruhiko Fukuda; Taro Shibata; Takuya Fukushima; Yoshifusa Takatsuka; Shuichi Ikeda; Masato Masuda; Haruhisa Nagoshi; Ryuzo Ueda; Kazuo Tamura; Masayuki Sano; Saburo Momita; Kazunari Yamaguchi; Fumio Kawano; Shuichi Hanada; Kensei Tobinai; Masanori Shimoyama; Tomomitsu Hotta; Masao Tomonaga
Journal:  J Clin Oncol       Date:  2007-10-29       Impact factor: 44.544

8.  Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.

Authors:  Takeshi Sugio; Koji Kato; Takatoshi Aoki; Takanori Ohta; Noriyuki Saito; Shuro Yoshida; Ichiro Kawano; Hideho Henzan; Masanori Kadowaki; Ken Takase; Tsuyoshi Muta; Kohta Miyawaki; Takuji Yamauchi; Takahiro Shima; Shuichiro Takashima; Yasuo Mori; Goichi Yoshimoto; Kenjiro Kamezaki; Katsuto Takenaka; Hiromi Iwasaki; Ryosuke Ogawa; Yuju Ohno; Tetsuya Eto; Tomohiko Kamimura; Toshihiro Miyamoto; Koichi Akashi
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-21       Impact factor: 5.742

9.  Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation.

Authors:  Kenji Motohashi; Taisei Suzuki; Kumiko Kishimoto; Ayumi Numata; Yuki Nakajima; Takayoshi Tachibana; Rika Ohshima; Hideyuki Kuwabara; Masatsugu Tanaka; Naoto Tomita; Yoshiaki Ishigatsubo; Shin Fujisawa
Journal:  Int J Hematol       Date:  2013-06-26       Impact factor: 2.319

10.  Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.

Authors:  Takashi Ishida; Tatsuro Jo; Shigeki Takemoto; Hitoshi Suzushima; Kimiharu Uozumi; Kazuhito Yamamoto; Naokuni Uike; Yoshio Saburi; Kisato Nosaka; Atae Utsunomiya; Kensei Tobinai; Hiroshi Fujiwara; Kenji Ishitsuka; Shinichiro Yoshida; Naoya Taira; Yukiyoshi Moriuchi; Kazunori Imada; Toshihiro Miyamoto; Shiro Akinaga; Masao Tomonaga; Ryuzo Ueda
Journal:  Br J Haematol       Date:  2015-03-02       Impact factor: 6.998
View more
  2 in total

1.  EPOCH regimen as salvage therapy for adult T-cell leukemia-lymphoma.

Authors:  Eo Toriyama; Yoshitaka Imaizumi; Hiroaki Taniguchi; Jun Taguchi; Jun Nakashima; Hidehiro Itonaga; Shinya Sato; Koji Ando; Yasushi Sawayama; Tomoko Hata; Takuya Fukushima; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2018-04-12       Impact factor: 2.490

2.  Severe graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with residual mogamulizumab concentration.

Authors:  Hiroki Hosoi; Toshiki Mushino; Akinori Nishikawa; Hisako Hashimoto; Shogo Murata; Kazuo Hatanaka; Shinobu Tamura; Nobuyuki Hanaoka; Norio Shimizu; Takashi Sonoki
Journal:  Int J Hematol       Date:  2018-04-18       Impact factor: 2.490
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.